

University of Wollongong Research Online

Faculty of Science - Papers (Archive)

Faculty of Science, Medicine and Health

2010

Preclinical Evaluation of Novel All-in-one Formulations of 5-Fluorouracil and Folinic Acid with Reduced Toxicity Profiles - Supplementary Data

Tamantha K. Stutchbury *University of Wollongong*

Kara L. Vine
University of Wollongong

Julie M. Locke
University of Wollongong

Jeremy S. Chrisp Jeremy Chrisp & Associates, Hunters Hill

John B. Bremner
University of Wollongong

See next page for additional authors

Publication Details

This supplementary data is related to the following article: Stutchbury, T.K. et al., Preclinical Evaluation of Novel All-in-one Formulations of 5-Fluorouracil and Folinic Acid with Reduced Toxicity Profiles, Anti-Cancer Drugs, 2010 (in press).

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: research-pubs@uow.edu.au



Preclinical Evaluation of Novel All-in-one Formulations of 5-Fluorouracil and Folinic Acid with Reduced Toxicity Profiles - Supplementary Data

Abstract

Objectives: 5-Fluorouracil (5-FU) in combination with its synergistic biomodulator folinic acid maintains a pivotal position in cancer chemotherapy. However, clinical limitations persist with the administration of these drugs in combination including phlebitis and catheter blockages, which are associated with reduced efficacy and/or quality of life for patients. We have previously reported novel all-in-one, pH neutral, parenteral 5-FU and folinic acid formulations (termed Fluorodex) incorporating beta-cyclodextrins. Fluorodex maintains potency while overcoming the accepted incompatibility of 5-FU and folinic acid.

Methods: We performed toxicological, pharmacokinetic and biodistribution, and efficacy evaluations of Fluorodex compared to 5-FU:folinic acid using several administration routes and schedules in two rodent models. These were compared to dose-matched sequential administration of 5-FU:folinic acid.

Results: Fluorodex showed bioequivalence to 5-FU:folinic acid as assessed by tissue distribution and pharmacokinetics of 5-FU, but was generally better tolerated as determined by weight loss, hematological and other clinical parameters. Compared to 5-FU:folinic acid, Fluorodex was also associated with reduced phlebitis using a rabbit ear vein model. Furthermore, equivalent to enhanced efficacy of Fluorodex compared to 5-FU:folinic acid against human carcinoma tumour models in mice was observed.

Conclusions: These novel all-in-one formulations represent a superior injectable form of 5- FU that allows co-delivery of folinic acid. This should translate to improved patient tolerability with potential for enhanced efficacy.

Disciplines

Life Sciences | Physical Sciences and Mathematics | Social and Behavioral Sciences

Publication Details

This supplementary data is related to the following article: Stutchbury, T.K. et al., Preclinical Evaluation of Novel All-in-one Formulations of 5-Fluorouracil and Folinic Acid with Reduced Toxicity Profiles, Anti-Cancer Drugs, 2010 (in press).

Authors

Tamantha K. Stutchbury, Kara L. Vine, Julie M. Locke, Jeremy S. Chrisp, John B. Bremner, Philip R. Clingan, and Marie Ranson

Stutchbury et al.

Supplementary Data

Table S1 Haematology parameters – male rats

	β-CD(HP) control			FD(HP)			5FU:FA		
	Mean	SD	Ν	Mean	SD	Ν	Mean	SD	Ν
WBC (x10 ⁹ /L)	8.43	1.39	4	2.40	1.10	4	2.33	2.70	4
Neutrophils	1.08	0.30	4	0.95	1.70	4	1.45	2.70	4
Lymphocytes	7.03	1.03	4	1.35	0.68	4	0.90	0.54	4
Monocytes	0.23	0.10	4	0.10	0.00	4	0.10	0.00	4
Eosinophils	0.1	0.00	4	0.1	0.00	4	0.1	0.00	4
RBC (x10 ¹² /L)	6.79	0.28	4	6.30	1.73	4	5.29	1.95	4
Hgb (g/L)	144.00	4.69	4	135.00	35.52	4	116.00	44.58	4
Hct (L/L)	0.43	0.02	4	0.39	0.10	4	0.33	0.13	4
MCV (fL)	62.95	1.41	4	61.80	1.50	4	61.30	2.51	4
MCH (pg)	21.20	0.32	4	21.45	0.31	4	21.88	0.39	4
MCHC (g/L)	336.75	4.11	4	347.50	3.51	4	357.25	8.96	4
Plt (x10 ⁹ /L)	1120.50	133.68	4	315.00	527.44	3	111.25	216.50	4

WBC: while blood cell; RBC: red blood cell; Hgb: hemoglobin; Hct: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; Plt: platelets.

Table S2 Haematology parameters – female rats

	β-CD(HP) control			FD(HP)			5FU:FA		
	Mean	SD	Ν	Mean	SD	Ν	Mean	SD	Ν
WBC (x10 ⁹ /L)	5.95	0.70	4	2.30	0.69	4	1.10	0.35	4
Neutrophils	0.75	0.39	4	0.10	0.00	4	0.1	0.00	4
Lymphocytes	5.08	0.710	4	2.15	0.73	4	1.10	0.35	4
Monocytes	0.10	0.00	4	0.10	0.00	4	0.1	0.00	4
Eosinophils	0.10	0.00	4	0.1	0.00	4	0.1	0.00	4
RBC (x10 ¹² /L)	6.22	0.28	4	5.29	0.20	4	4.86	0.22	4
Hgb (g/L)	132.00	6.38	4	113.25	5.38	4	100.75	3.50	4
Hct (L/L)	0.39	0.01	4	0.31	0.01	4	0.29	0.01	4
MCV (fL)	62.60	1.89	4	57.93	0.92	4	59.60	0.66	4
MCH (pg)	21.23	0.83	4	21.48	0.33	4	20.78	0.76	4
MCHC (g/L)	339.00	6.22	4	370.50	4.43	4	348.25	9.18	4
Plt (x10 ⁹ /L)	1049.50	92.31	4	44.50	16.84	4	3.25	4.50	4

WBC: while blood cell; RBC: red blood cell; Hgb: hemoglobin; Hct: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; Plt: platelets.